Christina A. Fennella, Giulia A. Marchettia, b, Scott S. Davisa, Andualem D. Mossiea 
Abstract
The American Cancer Society (ACS) has developed guidelines for the use of the prophylactic human papillomavirus (HPV) vaccine for the prevention of cervical intraepithelial neoplasia and cervical cancer. Recent increases in incidence and survival of oropharyngeal cancers in the United States have been attributed to human papillomavirus (HPV) infection. The epidemiology of oral HPV among people who use drugs or HIV-positive is not well described. The objective of this study is to determinants of oral human papillomavirus (HPV) among HIV-positive women were investigated by testing them for HPV DNA. At interview information was obtained and a oropharngeal lavage sample was collected for polymerase chain reaction-based HPV testing.
Keywords: Human papillomavirus; HIV-positive; cervical cancer; HPV DNA
Copyright © 2015 by The American Society for BioMedicine and BM-Publisher, Inc.
1. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52:342–362. [PubMed]
2. Harper DM, Franco EL, Wheeler CM, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364:1757–1765. [PubMed]
3. Russomano F, Paz BR, Camargo MJ, et al. Recurrence of cervical intraepithelial neoplasia in human immunodeficiency virus-infected women treated by means of electrosurgical excision of the transformation zone (LLETZ) in Rio de Janeiro, Brazil. Sao Paulo Med J 2013; 131(6):405–10. [PubMed]
4. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796–802. [PubMed]
5. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 1994; 169:235–240. [PubMed]
6. Blumenthal PD, Gaffikin. L, Chirenje ZM, et al. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int J Gynaecol Obstet 2001; 72:47–53. [PubMed]
7.Wright TC Jr, Denny L, Kuhn L, et al. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000; 283:81–86.[PubMed]
8. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000; 9:945–951. [PubMed]
9. Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120–2129. [PubMed]
10. Palefsky JM. Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. Proceedings of the 26th International Papillomavirus Conference; July 3-8, 2010; Montreal, Quebec, Canada.
11. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401–411. [PubMed]
12. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006;119:2620–2623. [PubMed]
13.Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst.2008; 100:261–269. [PubMed]
14. Marur S, D’Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11(8):781–789. [PubMed]
15. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24S3(23):S1–S10. [PubMed]
16. Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Dis Markers 2007; 23(4):213–227. [PubMed]
17.Koshiol J, Rottuno M, Gillison ML, et al. Assessment of human papillomavirus in lung tumor tissue. J Natl Cancer Inst 2011; 103:501–507. [PubMed]
18. Ryerson AB, Peters ES, Coughlin SS, et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 2008; 113:2901–2909. [PubMed]
19. Adelstein DJ, Ridge JA, Gillison ML, et al. Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 2009; 31:1393–1422. [PubMed]
20. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24:5630–5636.. [PubMed]
21. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100:407–420. [PubMed]
22. Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004; 96:449–455. [PubMed]
23. Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95:1772–1783. [PubMed]
24. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. United States; 2011;29: 4294–4301. [PubMed]
25. Vlahov D, Anthony JC, Muñoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: Description of methods and characteristics of participants. National Institute on Drug Abuse Monograph: Longitudinal Studies of HIV Infection in Intravenous Drug Users. 1991. pp. 75–100. [PubMed]
26. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncology. England; 2005. p. 204. [PubMed]
27.Phelan DF, Gange SJ, Ahdieh-Grant L, et al. Determinants of Newly Detected Human Papillomavirus Infection in HIV-Infected and HIV-Uninfected Injection Drug Using Women. Sex Transm Dis 2009; 36:149–156. [PubMed]
28. Agenor M, Peitzmeier S, Gordon AR, et al. Sexual Orientation Identity Disparities in Awareness and Initiation of the Human Papillomavirus Vaccine Among U.S. Women and Girls: A National Survey. Ann Intern Med. United States 2015; 163: 99–106. [PubMed]
29. Herrero R, Quint W, Hildesheim A, et al. Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica. PLoS One 2013; 8. [PubMed]
30. Muller K, Kazimiroff J, Fatahzadeh M. Oral Human Papillomavirus Infection and Oral Lesions in HIV-Positive and HIV-Negative Dental Patients. J Infect Dis 2015; 212(5):760-8. [PubMed]
31. Kim JJ. Focus on research: Weighing the benefits and costs of HPV vaccination of young men. N Engl J Med 2011; 364:393–395. [PubMed]
Limited access article
Purchase this article at rate $55.00 and received Full-Text/PDF
For any technique error please contact us and will be response to sending purchase article by email.
Thank you for visiting American Journal of BioMedicine. * = Required fields
[gravityform id=”6″ name=”Feedback”]
References
This article with limited access need to be buy, before continue with your purchase please read carefully the AJBM terms and conditions of purchase.
You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use. Use the coding below to purchase your article as PDF by credit card, debit card, payball will be asked to supply your billing card information.
